BioSpace News Archive

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today announced that Eric. A. Adams, President and CEO, and Dr. Eric Hsu, Senior Vice President of Pre-Clinical Research & Development, will present at H.C. Wainwright Ophthalmology Virtual Conference.

Adial Pharmaceuticals, Inc. today announced it will host a conference call at 11:00 A.M. Eastern Time on Friday, August 20, 2021 to provide a clinical update and discuss the latest business developments.

Sen-Jam, a life-science startup led by Registered Pharmacist Jacqueline Iversen, has partnered with researcher Ashley St. John PhD of the Duke-NUS Medical School in Singapore, to trial a novel combination of two proven drug molecules that may work pre-emptively to stop the progression of COVID to the Severe Acute Respiratory Syndrome (SARS) stage.

ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2021.

Brickell Biotech, Inc., a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced financial results for the second quarter ended June 30, 2021 and provided a corporate update.

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the second quarter ended June 30, 2021 and provided clinical development and operational highlights.

4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the second quarter of 2021, and provided operational highlights.

NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, reported financial results for the quarter ended June 30, 2021.

Evoke Pharma, Inc., a specialty pharmaceutical company focused primarily on treatments for gastrointestinal diseases, announced its financial results for the second quarter that ended June 30, 2021 which includes recent corporate developments.

Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today provided a corporate update and reported financial results for the quarter ended June 30, 2021.